FutureMeds Appoints Tom O'Connor Jackson as Global Brand and Marketing Director
As FutureMeds’ Global Brand and Marketing Director, Tom will play a crucial role in enhancing FutureMeds' marketing and branding strategies to provide improved services to CROs and sponsors, foster strong relationships with clinical research professionals and increase patient engagement.
FutureMeds appointed Tom O'Connor Jackson as Global Brand and Marketing Director. He will be responsible for building an authentic, compelling, and consistent brand experience for partners, clinical research professionals, and patients.
Tom comes with over 20 years of experience in advertising, UX, and has an impressive track record encompassing multiple industries. He helped commercial global brands such as TimeOut, HSBC, and The Guardian, charities like Age International and Shelter and startups and scale-ups to grow their businesses. His clinical experience and understanding of the dynamics of the clinical research industry predominantly comes through working with a pharmacovigilance software provider of Pfizer and supporting FutureMeds since the inception of the company.
His expertise in creating strong brands, fostering strong relationships through brand experience and improved communication will be invaluable in strengthening FutureMeds' marketing and branding strategies. This will enable our fast-growing company to provide an improved and more efficient service to CROs and sponsors, build strong relationships with clinical research professionals and increase patient engagement.
“I’m excited to help connect an amazing worldwide community through a common purpose. We know clinical research can enhance and even save lives, so building strong relationships between sponsor partners, medical professionals, and patients is paramount to finding answers faster together. Patient-centricity, local expertise, and innovative technology will be essential in accelerating the research process, enhancing the trial experience, and ensuring data quality.”
- Tom O’Connor Jackson, Global Brand and Marketing Director at FutureMeds
Tom is a trained NLP practitioner and has developed a sophisticated personas profiling framework for targeting, engaging and communicating with the right customers. He is passionate about developing authentic brand purposes, understanding the importance of brand activations, and leveraging behavioural economics to boost conversion rates and drive progress.
In his new role, Tom will be responsible for building an authentic, compelling, and consistent brand experience for partners, professionals, and patients. He will develop targeted campaigns to attract high-quality patients and partners, help enhance the brand experience for increased retention, and spearhead digital strategy to improve process efficiency. Tom will also work closely with local teams, equipping them with a flexible brand architecture that supports their unique needs.
With Tom O'Connor's appointment as Global Brand and Marketing Director, FutureMeds continues to demonstrate its commitment to improving patient engagement and professional collaboration, facilitating the successful completion of clinical trials and, ultimately, transforming and saving lives.
FutureMeds is a fast-growing independent Dedicated Research Site Network supporting pharmaceutical companies, Sponsors and CROs and contributing to research to find effective treatments and medications for all patients who need them.
FutureMeds’ Dedicated Research Site teams strive to accelerate study timelines, streamline processes, lower costs and improve data quality to help accelerate patient access to new treatments.
Through acquisitions and a strategic focus on patient experience, FutureMeds has developed qualified patient pools across Europe that enables faster patient enrollment and strong retention and help generate more accurate results.
Follow us on LinkedIn
Follow FutureMeds on LinkedIn and join a growing group of engaged, passionate healthcare and pharmaceutical professionals who are on a mission to accelerate the drug development process and achieve regulatory approval faster so patients can safely access the very latest treatments as soon as possible.